EDUCATION

Graduate Degree

MMSc
  • Harvard Medical School , Boston , MA

Medical School

  • Brown University , 2003 , Providence , RI

Internship

Pediatrics
  • Boston Children's Hospital/Boston Medical Center , 2004 , Boston , MA

Residency

Pediatrics
  • Boston Combined Residency Program (BCRP) , 2006 , Boston , MA

Fellowship

Pediatric Hematology-Oncology
  • Boston Children's Hospital/ Dana-Farber Cancer Institute , 2010 , Boston , MA

PROFESSIONAL HISTORY

 Rachael Grace, MD, MMSc, is a pediatric hematologist and clinical researcher at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. She is the medical director of both the Hematology Ambulatory Program and the Hematology Clinical Research Program. Dr. Grace enjoys clinical care of pediatric patients and her research interests are focused on improving outcomes in the care and treatment of individuals with immune cytopenias.

Dr. Grace is the lead investigator for the Pyruvate Kinase Deficiency Natural History Study, a global registry for patients with PK deficiency. She is a site investigator for the DRIVE-PK and ACTIVATE mitapivat (AG-348) clinical trials and the PEAK registry. She is also involved in multiple clinical research studies in immune cytopenias and is the director of the coordinating center for the ITP Consortium of North America (ICON), a research network of pediatric idiopathic thrombocytopenic purpura investigators from over 50 institutions in the U.S. and Canada.

Dr. Grace is an Associate Professor of Pediatrics at Harvard Medical School. She received her MD at Brown University and received her master’s degree in clinical research at Harvard Medical School. Dr. Grace completed her residency at Boston Children’s Hospital and completed her pediatric hematology/oncology fellowship at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

 

CERTIFICATIONS

  • American Board of Pediatrics, General Pediatrics
  • American Board of Pediatrics, Pediatric Hematology and Oncology

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. An Update on Pediatric Immune Thrombocytopenia (ITP): Differentiating Primary ITP, IPD, and PID. Blood. 2021 Sep 03. View abstract
  2. Health-Related Quality of Life and Fatigue in Children and Adults with Pyruvate Kinase Deficiency. Blood Adv. 2021 Sep 01. View abstract
  3. Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol. BMJ Open. 2021 Aug 27; 11(8):e044885. View abstract
  4. Response to rituximab in children and adults with immune thrombocytopenia (ITP). Res Pract Thromb Haemost. 2021 Aug; 5(6):e12587. View abstract
  5. Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost. 2021 08; 19(8):2082-2088. View abstract
  6. The SSC platelet immunology register of VITT and VIITP: Toward standardization of laboratory and clinical parameters. J Thromb Haemost. 2021 08; 19(8):2094-2095. View abstract
  7. Pyruvate kinase deficiency in children. Pediatr Blood Cancer. 2021 Sep; 68(9):e29148. View abstract
  8. Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology. J Thromb Haemost. 2021 Sep; 19(9):2348-2354. View abstract
  9. Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost. 2021 06; 19(6):1585-1588. View abstract
  10. Preoperative hematocrit and platelet count are associated with blood loss during spinal fusion for children with neuromuscular scoliosis. J Perioper Pract. 2021 Apr 07; 1750458920962634. View abstract
  11. Quality of life is an important indication for second-line treatment in children with immune thrombocytopenia. Pediatr Blood Cancer. 2021 Jun; 68(6):e29023. View abstract
  12. Refractory autoimmune cytopenias in pediatric Evans syndrome with underlying systemic immune dysregulation. Eur J Haematol. 2021 Jun; 106(6):783-787. View abstract
  13. Comorbidities and complications in adults with pyruvate kinase deficiency. Eur J Haematol. 2021 Apr; 106(4):484-492. View abstract
  14. International survey on Helicobacter pylori testing in patients with immune thrombocytopenia: Communication of the platelet immunology scientific and standardization committee. J Thromb Haemost. 2021 01; 19(1):287-296. View abstract
  15. Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method. Res Pract Thromb Haemost. 2021 Jan; 5(1):69-80. View abstract
  16. Management of pyruvate kinase deficiency in children and adults. Blood. 2020 09 10; 136(11):1241-1249. View abstract
  17. The variable manifestations of disease in pyruvate kinase deficiency and their management. Haematologica. 2020 09 01; 105(9):2229-2239. View abstract
  18. Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1. J Allergy Clin Immunol. 2020 11; 146(5):1194-1200.e1. View abstract
  19. Pyruvate kinase deficiency in a newborn with extramedullary hematopoiesis in the skin. Blood. 2020 08 06; 136(6):770. View abstract
  20. Characterization of the severe phenotype of pyruvate kinase deficiency. Am J Hematol. 2020 Jul 03. View abstract
  21. Fatigue in children and adolescents with immune thrombocytopenia. Br J Haematol. 2020 10; 191(1):98-106. View abstract
  22. COVID-19 presenting with autoimmune hemolytic anemia in the setting of underlying immune dysregulation. Pediatr Blood Cancer. 2020 09; 67(9):e28382. View abstract
  23. The pyruvate kinase (PK) to hexokinase enzyme activity ratio and erythrocyte PK protein level in the diagnosis and phenotype of PK deficiency. Br J Haematol. 2021 03; 192(6):1092-1096. View abstract
  24. The role of romiplostim for pediatric patients with immune thrombocytopenia. Ther Adv Hematol. 2020; 11:2040620720912992. View abstract
  25. The variable manifestations of disease in pyruvate kinase deficiency and their management. Haematologica. 2020 Mar 12. View abstract
  26. Genotype-phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency. Am J Hematol. 2020 05; 95(5):472-482. View abstract
  27. Development of the pyruvate kinase deficiency diary and pyruvate kinase deficiency impact assessment: Disease-specific assessments. Eur J Haematol. 2020 May; 104(5):427-434. View abstract
  28. Genetic variants in toll-like receptor 4 are associated with lack of steroid-responsiveness in pediatric ITP patients. Am J Hematol. 2020 04; 95(4):395-400. View abstract
  29. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019 12 10; 3(23):3829-3866. View abstract
  30. Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency. N Engl J Med. 2019 09 05; 381(10):933-944. View abstract
  31. Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. Am J Hematol. 2019 07; 94(7):741-750. View abstract
  32. Pediatric Hematology. Hematol Oncol Clin North Am. 2019 06; 33(3):xiii-xiv. View abstract
  33. Association of a positive direct antiglobulin test with chronic immune thrombocytopenia and use of second line therapies in children: A multi-institutional review. Am J Hematol. 2019 04; 94(4):461-466. View abstract
  34. How we manage patients with pyruvate kinase deficiency. Br J Haematol. 2019 03; 184(5):721-734. View abstract
  35. The burden of disease in pyruvate kinase deficiency: Patients' perception of the impact on health-related quality of life. Eur J Haematol. 2018 Dec; 101(6):758-765. View abstract
  36. Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica. 2019 02; 104(2):e51-e53. View abstract
  37. Ofatumumab for acute treatment and prophylaxis of a patient with multiple relapses of acquired thrombotic thrombocytopenic purpura. J Thromb Thrombolysis. 2018 Jul; 46(1):81-83. View abstract
  38. Red Blood Cell Enzyme Disorders. Pediatr Clin North Am. 2018 06; 65(3):579-595. View abstract
  39. Physician decision making in selection of second-line treatments in immune thrombocytopenia in children. Am J Hematol. 2018 07; 93(7):882-888. View abstract
  40. Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. Blood. 2018 05 17; 131(20):2183-2192. View abstract
  41. The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. J Thromb Thrombolysis. 2018 Feb; 45(2):306-314. View abstract
  42. Platelet Function in ITP, Independent of Platelet Count, Is Consistent Over Time and Is Associated with Both Current and Subsequent Bleeding Severity. Thromb Haemost. 2018 01; 118(1):143-151. View abstract
  43. Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants. Pediatr Blood Cancer. 2018 Jan; 65(1). View abstract
  44. Second-line therapies in immune thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):698-706. View abstract
  45. Increasing observation rates in low-risk pediatric immune thrombocytopenia using a standardized clinical assessment and management plan (SCAMP® ). Pediatr Blood Cancer. 2017 05; 64(5). View abstract
  46. Exome sequencing results in successful diagnosis and treatment of a severe congenital anemia. Cold Spring Harb Mol Case Stud. 2016 Jul; 2(4):a000885. View abstract
  47. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. Pediatr Blood Cancer. 2016 08; 63(8):1407-13. View abstract
  48. Vitamin B12 Deficiency Presenting with Neurological Dysfunction in an Adolescent. Pediatr Neurol. 2016 09; 62:66-70. View abstract
  49. Erythrocyte pyruvate kinase deficiency: 2015 status report. Am J Hematol. 2015 Sep; 90(9):825-30. View abstract
  50. Thrombopoietin-receptor agonists in children with immune thrombocytopenia. Lancet. 2015 Oct 24; 386(10004):1606-9. View abstract
  51. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood. 2015 Aug 13; 126(7):873-9. View abstract
  52. Image-guided core needle biopsy in the diagnosis of malignant lymphoma. Eur J Surg Oncol. 2015 Jul; 41(7):852-8. View abstract
  53. The utility of the DDAVP challenge test in children with low von Willebrand factor. Br J Haematol. 2015 Sep; 170(6):884-6. View abstract
  54. Treatment and outcomes of immune cytopenias following solid organ transplant in children. Pediatr Blood Cancer. 2015 02; 62(2):214-218. View abstract
  55. The use of erythropoietin-stimulating agents versus supportive care in newborns with hereditary spherocytosis: a single centre's experience. Eur J Haematol. 2014 Aug; 93(2):161-4. View abstract
  56. Standardized clinical assessment and management plans (SCAMPs): perspectives on a new method to understand treatment decisions and outcomes in immune thrombocytopenia. Semin Hematol. 2013 Jan; 50 Suppl 1:S31-8. View abstract
  57. A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood. 2012 Apr 05; 119(14):3263-8. View abstract
  58. Trends in anti-D immune globulin for childhood immune thrombocytopenia: usage, response rates, and adverse effects. Am J Hematol. 2012 Mar; 87(3):315-7. View abstract
  59. Applicability of 2009 international consensus terminology and criteria for immune thrombocytopenia to a clinical pediatric population. Pediatr Blood Cancer. 2012 Feb; 58(2):216-20. View abstract
  60. Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. Pediatr Blood Cancer. 2012 Feb; 58(2):221-5. View abstract
  61. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011 Feb; 152(4):452-9. View abstract
  62. Unsuspected pulmonary emboli in pediatric oncology patients: detection with MDCT. AJR Am J Roentgenol. 2010 May; 194(5):1216-22. View abstract
  63. Genetic studies in pediatric ITP: outlook, feasibility, and requirements. Ann Hematol. 2010 Jul; 89 Suppl 1:S95-103. View abstract
  64. Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea. Am J Hematol. 2010 Feb; 85(2):135-7. View abstract
  65. Compliance with immunizations in splenectomized individuals with hereditary spherocytosis. Pediatr Blood Cancer. 2009 Jul; 52(7):865-7. View abstract
  66. Rituximab for adolescents with haemophilia and high titre inhibitors. Haemophilia. 2006 May; 12(3):218-22. View abstract
  67. Cardiac presentation of ALK positive anaplastic large cell lymphoma. Eur J Haematol. 2005 Dec; 75(6):511-4. View abstract
  68. Ivermectin is better than benzyl benzoate for childhood scabies in developing countries. J Paediatr Child Health. 2002 Aug; 38(4):401-4. View abstract
  69. Transmembrane versus soluble stem cell factor expression in human testis. J Androl. 2000 Jul-Aug; 21(4):579-85. View abstract
  70. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 1997 Dec; 99(4):939-44. View abstract
  71. Ligand linked assembly of Scapharca dimeric hemoglobin. J Biol Chem. 1997 Feb 28; 272(9):5689-94. View abstract